Rubius Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RUBY research report →
About the company
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions.
- CEO
- Laurence A. Turka
- IPO
- 2018
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $0
- P/E
- -0.02
- P/S
- 0.00
- P/B
- 0.34
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -238.11%
- ROIC
- -1099.41%
- Revenue
- $0 · 0.00%
- Net Income
- $-230,863,000 · -22.26%
- EPS
- $-2.56 · -19.07%
- Op Income
- $-178,446,000
- FCF YoY
- -4.49%
- 52W High
- $0.38
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 2.21
- Avg Volume
- 99.53K
Get TickerSpark's AI analysis on RUBY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 23 | Appelhans Dannielle | sell | 10,385 |
| Feb 1, 23 | CAGNONI PABLO J | sell | 8,448 |
| Jan 31, 23 | Appelhans Dannielle | other | 7,500 |
| Jan 31, 23 | Appelhans Dannielle | other | 7,500 |
| Feb 1, 23 | Appelhans Dannielle | sell | 3,878 |
| Jan 31, 23 | CAGNONI PABLO J | other | 25,000 |
| Jan 31, 23 | CAGNONI PABLO J | other | 25,000 |
| Jan 31, 23 | CAGNONI PABLO J | sell | 7,240 |
| Jan 29, 23 | CAGNONI PABLO J | other | 21,250 |
| Jan 29, 23 | CAGNONI PABLO J | other | 21,250 |
Our RUBY coverage
Recent articles, reports, and earnings notes.
No research on RUBY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RUBY report →Similar companies
Peers in the same neighborhood.